Original Research J Clin Psychiatry April 2020

Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study

JCP 2020;81(3):10.4088/JCP.19m12979

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2020;81(3):10.4088/JCP.19m12979 Clinical Summary Adult attention-deficit/hyperactivity disorder is often underdiagnosed, functionally impairing, and difficult to treat when current options are limited. This trial tests whether guanfacine extended-release, a nonstimulant already used in pediatric ADHD, improves core symptoms in adults without introducing major safety problems. FAQ Does guanfacine extended-release work for adults with ADHD? 11 questions
Key Takeaways Dose-optimized guanfacine extended-release showed separation from placebo by week 4 on the ADHD-RS-IV total score, with benefits sustained through week 10, suggesting clinicians should allow several weeks of titration before judging efficacy. 6 takeaways Clinical Guide Which adults with attention-deficit/hyperactivity disorder fit the patient profile studied for guanfacine extended-release treatment? 5 steps Clinical Guide How should clinicians start and monitor guanfacine extended-release in adults with attention-deficit/hyperactivity disorder based on the trial protocol and safety findings? 8 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe